19.595 USD
+0.05 (+0.28%)
Overall PTN gets a fundamental rating of 2 out of 10. We evaluated PTN against 534 industry peers in the Biotechnology industry. PTN may be in some trouble as it scores bad on both profitability and health. PTN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PTN has reported negative net income.
PTN had a negative operating cash flow in the past year.
In the past 5 years PTN always reported negative net income.
PTN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PTN has a worse Return On Assets (-625.34%) than 97.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -625.34% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTN has a better Gross Margin (1255.00%) than 100.00% of its industry peers.
In the last couple of years the Gross Margin of PTN has declined.
PTN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1255% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTN has been increased compared to 1 year ago.
PTN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PTN has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -169.70, we must say that PTN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PTN (-169.70) is worse than 97.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -169.7 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
PTN has a Current Ratio of 0.38. This is a bad value and indicates that PTN is not financially healthy enough and could expect problems in meeting its short term obligations.
PTN's Current ratio of 0.38 is on the low side compared to the rest of the industry. PTN is outperformed by 93.63% of its industry peers.
PTN has a Quick Ratio of 0.38. This is a bad value and indicates that PTN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.38, PTN is not doing good in the industry: 93.45% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
The earnings per share for PTN have decreased strongly by -109.14% in the last year.
Looking at the last year, PTN shows a decrease in Revenue. The Revenue has decreased by -7.42% in the last year.
PTN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.52% yearly.
EPS 1Y (TTM)-109.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
Revenue 1Y (TTM)-7.42%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.65% on average over the next years. This is quite good.
Based on estimates for the next years, PTN will show a very strong growth in Revenue. The Revenue will grow by 162.67% on average per year.
EPS Next Y98.1%
EPS Next 2Y41.88%
EPS Next 3Y27.03%
EPS Next 5Y15.65%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PTN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
PTN is valuated quite expensively with a Price/Forward Earnings ratio of 28.53.
91.57% of the companies in the same industry are more expensive than PTN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.56. PTN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.53 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTN's earnings are expected to grow with 27.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.88%
EPS Next 3Y27.03%
5. Dividend
5.1 Amount
No dividends for PTN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSEARCA:PTN (12/1/2025, 11:53:56 AM)
19.595
+0.05 (+0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.86%
Inst Owner Change-10.33%
Ins Owners0.75%
Ins Owner Change0.19%
Market Cap35.08M
Revenue(TTM)4.49M
Net Income(TTM)-26.95M
Analysts80
Price Target7.14 (-63.56%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48%
Min EPS beat(2)24.29%
Max EPS beat(2)71.71%
EPS beat(4)3
Avg EPS beat(4)25.29%
Min EPS beat(4)-5.65%
Max EPS beat(4)71.71%
EPS beat(8)3
Avg EPS beat(8)-26.04%
EPS beat(12)6
Avg EPS beat(12)-12.52%
EPS beat(16)8
Avg EPS beat(16)-16.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4900%
EPS NQ rev (3m)-4900%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 28.53 | ||
| P/S | 100.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-59.5
EYN/A
EPS(NY)0.69
Fwd EY3.5%
FCF(TTM)-15.05
FCFYN/A
OCF(TTM)-15.05
OCFYN/A
SpS0.2
BVpS-3.56
TBVpS-3.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -625.34% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1255% | ||
| FCFM | N/A |
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.53% | ||
| Cap/Sales | 1.4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | -169.7 |
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)120.27%
Cap/Depr(5y)96.16%
Cap/Sales(3y)9.17%
Cap/Sales(5y)16.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-109.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
EPS Next Y98.1%
EPS Next 2Y41.88%
EPS Next 3Y27.03%
EPS Next 5Y15.65%
Revenue 1Y (TTM)-7.42%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
EBIT growth 1Y1.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.15%
OCF growth 3YN/A
OCF growth 5YN/A
PALATIN TECHNOLOGIES INC / PTN FAQ
What is the fundamental rating for PTN stock?
ChartMill assigns a fundamental rating of 2 / 10 to PTN.
Can you provide the valuation status for PALATIN TECHNOLOGIES INC?
ChartMill assigns a valuation rating of 3 / 10 to PALATIN TECHNOLOGIES INC (PTN). This can be considered as Overvalued.
Can you provide the profitability details for PALATIN TECHNOLOGIES INC?
PALATIN TECHNOLOGIES INC (PTN) has a profitability rating of 1 / 10.
What is the financial health of PALATIN TECHNOLOGIES INC (PTN) stock?
The financial health rating of PALATIN TECHNOLOGIES INC (PTN) is 0 / 10.